uniQure N.V. (QURE)
13.22
-0.57 (-4.13%)
At close: Jan 14, 2025, 3:59 PM
13.89
5.03%
Pre-market Jan 15, 2025, 07:45 AM EST
undefined% (undefined)
| Bid | 13.3 |
| Market Cap | 706.71M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.95 |
| PE Ratio (ttm) | -2.67 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 13.8 |
| Volume | 1,057,566 |
| Avg. Volume (20D) | 2,184,052 |
| Open | 13.94 |
| Previous Close | 13.79 |
| Day's Range | 13.04 - 13.96 |
| 52-Week Range | 3.73 - 19.18 |
| Beta | undefined |
About QURE
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2014
Employees 480
Stock Exchange NASDAQ
Ticker Symbol QURE
Website https://www.uniqure.com
Analyst Forecast
According to 8 analyst ratings, the average rating for QURE stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 89.04% from the latest price.
Buy 75.00%
Hold 25.00%
Sell 0.00%
Next Earnings Release
uniQure N.V. is scheduled to release its earnings on Feb 26, 2025,
before market opens.
Analysts project revenue of $19.06M, reflecting a 184.95% YoY growth and earnings per share of -0.78, making a -49.02% decrease YoY.
Analysts project revenue of $19.06M, reflecting a 184.95% YoY growth and earnings per share of -0.78, making a -49.02% decrease YoY.
1 week ago ·
Source
-9.75%
UniQure shares are trading lower after the company...
Unlock content with
Pro Subscription
4 weeks ago ·
Source
+12.99%
UniQure shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $12 to $32.
